Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model

INTRODUCTION: On the basis of reductions in diabetic kidney disease (DKD) progression and major adverse cardiovascular events observed in the landmark CREDENCE trial, canagliflozin 100 mg received an extension to its EU marketing authorisation in July 2020 to include the treatment of DKD in people w...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Diabetes Ther
Main Authors: Willis, Michael, Nilsson, Andreas, Kellerborg, Klas, Ball, Philip, Roe, Rupert, Traina, Shana, Beale, Rebecca, Newell, Isabelle
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2020
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843731/
https://ncbi.nlm.nih.gov/pubmed/33263893
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00968-x
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki